Comparison of ultralongacting insulin, glargine and degludec in type2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000010447
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 5)pregnacy 6)Allergy for glargine and degludec 7)Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achievement rate of FPG <110mg/dl and PPG <180mg/dl after treatment with glargine or degludec
- Secondary Outcome Measures
Name Time Method 1)Glucose variability, CV. 2)Achievment rate of <110mg/dl of FPG or 180mg/dl of PPG 3)FPG and PPG after 2 weeks of treatment 4)days to achieve target 5)frequencies of hypoglycemia 6)Achievment rate of <130mg/dl of FPG or 200mg/dl of PPG 7)lipid control 8)MAGE and CV in CGM